Establishment Labs Announces Appointment of Antoun Nabhan, J.D. as Chief Financial Officer

Share Article

Establishment Labs, a global medical device company focused on breast implant technologies with a strong emphasis on product development and innovation, is pleased to announce that Antoun Nabhan, J.D., has joined the company as its Chief Financial Officer.

Logo Motiva Implants and Establishment Labs
"We look forward to introducing these innovative products to the U.S. market, and are working rapidly to initiate the clinical development program necessary to support U.S. approval.”

Establishment Labs, a global medical device company focused on breast implant technologies with a strong emphasis on product development and innovation, is pleased to announce that Antoun Nabhan, J.D., has joined the company as its Chief Financial Officer.

“We are very pleased to add Antoun to the senior leadership team. He brings experience in financial processes and systems, initial public offerings for medical device companies and strategic transactions. His portfolio of skills will be of critical importance to our team as we expand our product portfolio and seek U.S. approval for our products,” said Juan José Chacón Quirós, CEO of Establishment Labs.

Mr. Nabhan joins Establishment Labs from Raptor Pharmaceuticals, Inc., where he served as Vice President of Corporate Development. Prior to that, he was Vice President of Corporate Development at medical device and diagnostics manufacturer Capnia, Inc. At Capnia, he served as principal finance and accounting executive and managed Capnia’s 2014 initial public offering.

Mr. Nabhan has also been Chief Financial Officer of Presidio Pharmaceuticals, Inc. and Vice President of Finance at Incellico, Inc. He held positions of increasing responsibility at Onyx Pharmaceuticals prior to its acquisition by Amgen. Mr. Nabhan received a B.A. from the University of Chicago and a J.D. from Harvard Law School.

“I am excited to join Establishment Labs, where the company’s years of R&D and innovation are leading to accelerating sales,” commented Mr. Nabhan, “The company’s core Motiva Implants® have become a leading brand, bringing important improvements in both patient satisfaction and safety to the silicone implant space. We look forward to introducing these innovative products to the U.S. market, and are working rapidly to initiate the clinical development program necessary to support U.S. approval.”

He added, “The company also has a deep base of intellectual property that will support expansion into other medical device arenas. Establishment Labs has an exceptionally skilled team, and I am pleased to be helping them execute on these growth strategies.”

About Establishment Labs:

Establishment Labs is a global, privately held, breast implant and medical technology company that designs, develops, manufactures and markets an innovative product portfolio consisting of advanced silicone-filled breast and body shaping implants (http://www.motivaimplants.com). Utilizing only the highest quality of medical grade silicones, the CE-marked Motiva Implants® line is rigorously scrutinized by professional Quality Engineers throughout the entire manufacturing process. All of its products are manufactured in full compliance with ISO and EU requirements, and are certified under the Medical Device Directive 93/42/EEC.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Luis Gutierrez
@MotivaImagine
Follow >
Motiva Implants
Like >
Motiva Implants

Visit website